Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction [0.03%]
替格瑞洛用于首次医疗接触的ST段抬高型心肌梗死患者
A W J Van&#x;t Hof,C M Gibson,S A O F Rikken et al.
A W J Van&#x;t Hof et al.
Background: Zalunfiban is a glycoprotein IIb/IIIa (integrin αIIbβ3) inhibitor designed for subcutaneous administration on first medical contact with patients with suspected ST-segment elevation myocardial infarction (ST...
Robert S Stern
Robert S Stern
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites [0.03%]
用于重度累及部位银屑病的口服肽类药物Icotropilra靶向治疗
Melinda Gooderham,Edward Lain,Robert Bissonnette et al.
Melinda Gooderham et al.
Background: Plaque psoriasis involving high-impact sites is difficult to treat. Icotrokinra, a targeted oral peptide that selectively binds interleukin-23 receptors, is a new treatment being investigated for this conditio...
Katja Vu Bartholdy,Niklas Dyrby Johansen,Kristoffer Grundtvig Skaarup et al.
Katja Vu Bartholdy et al.
Background: Adverse cardiac remodeling is common in people with chronic kidney disease and contributes to increased cardiovascular risk. Although sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown cardioprotecti...
Randomized Controlled Trial
NEJM evidence. 2025 Nov;4(11):EVIDoa2500158. DOI:10.1056/EVIDoa2500158 2025
Genetics of Cholesterol and Coronary Disease Risk across Six Global Ancestries [0.03%]
全球六种族群的胆固醇遗传学和冠状动脉疾病风险基因组学研究
Sarah M Urbut,Qiuli Chen,Yang Sui et al.
Sarah M Urbut et al.
Background: Clinical trials of low-density lipoprotein cholesterol (LDL-C)-lowering medicines have shown improvement in cardiovascular disease risk. However, representation across diverse communities in such trials is lim...
Sofiane Bendifallah,Horace Roman,Stéphane Suisse et al.
Sofiane Bendifallah et al.
Background: Diagnosis of endometriosis is a challenge. The recent development of a saliva-based micro-ribonucleic acid (miRNA) signature for the diagnosis of endometriosis may enable a timelier and less invasive approach,...
Multicenter Study
NEJM evidence. 2025 Nov;4(11):EVIDoa2400195. DOI:10.1056/EVIDoa2400195 2025
Age and Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer [0.03%]
年龄与转移性激素敏感性前列腺癌治疗强化的关系
Alicia K Morgans,Soumyajit Roy,Angela Y Jia et al.
Alicia K Morgans et al.
Background: Older men with metastatic hormone-sensitive prostate cancer (mHSPC) are more likely to have comorbid medical conditions and die from causes other than prostate cancer. We aimed to determine if age impacts the ...
Meta-Analysis
NEJM evidence. 2025 Nov;4(11):EVIDoa2500109. DOI:10.1056/EVIDoa2500109 2025
Julianne M O&#x;Daniel,Christine Kobelka,Kimberly Foss et al.
Julianne M O&#x;Daniel et al.
AbstractDirect-to-consumer genetic testing has become increasingly popular, offering individuals easy access to genetic data without the involvement of health care professionals. However, as availability grows, clinicians face challenges in...
Age Matters - Personalizing Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer [0.03%]
年龄有别——转移性雄激素敏感前列腺癌治疗强度个体化的选择
Jordan Ciuro,Bradley C Carthon
Jordan Ciuro
Long Live Random Forest - The Quiet, Long-Lasting Power of Statistical Learning for Molecular Diagnostics in the AI Era [0.03%]
随机森林万岁——统计学习在人工智能时代的分子诊断中的低调持久力量
Claudio Battiloro,Francesca Dominici
Claudio Battiloro